Morgan Stanley assumed coverage on shares of Denali Therapeutics (NASDAQ:DNLI – Free Report) in a report published on Friday, ...

Proficio Capital Partners LLC acquired a new stake in Denali Therapeutics Inc. (NASDAQ:DNLI – Free Report) during the 4th quarter, Holdings Channel reports. The fund acquired 25,210 shares of the ...

We recently compiled a list of the Jeff Bezos Investments in 2025: 12 Companies Bezos Is Investing In. In this article, we ...

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Denali Therapeutics (DNLI – Research Report), ...

Morgan Stanley analyst Sean Laaman assumed coverage of Denali Therapeutics (DNLI) with an Overweight rating and a price target of $33, down ...

In trading on Monday, shares of Denali Therapeutics Inc (Symbol: DNLI) entered into oversold territory, hitting an RSI reading of 29.2, after changing hands as low as $15.745 per share.

Three of VB's underlying holdings with notable upside to their analyst target prices are CG Oncology Inc (Symbol: CGON), Denali Therapeutics Inc (Symbol: DNLI), and Biohaven Ltd (Symbol ...

2seventy bio Inc (TSVT) is expected to report $-0.20 for 4Q. 908 Devices Inc (MASS) is expected to report $-0.39 for 4Q. ATN International Inc (ATNI) is expected to report $-0.24 for 4Q. Aclaris ...